Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis
NCT07686042
·
clinicaltrials.gov ↗
PHASE4
Phase
NOT_YET_RECRUITING
Status
12
Enrollment
OTHER
Sponsor class
Conditions
Autoimmune Encephalitis (AE)
Autoimmune Cerebellitis
Interventions
DRUG:
Blinatumomab
Sponsor
Beijing Tiantan Hospital